Mitomycin Markets Research Report Now Available at MarketPublishers.com
19 Oct 2011 • by Natalie Aster
LONDON – Each year a large number of people get gastric cancer, and about one thousand of those, who already have it, die. The cancer is most frequently discovered amid men over 55. Common methods of the gastric cancer treatment are surgery, chemotherapy, and radiotherapy. An increasing number of patients undergo mitomycin therapy.
New market research study “Mitomycin (Gastric Cancer) - Analysis and Forecasts to 2020” developed by GlobalData provides unprejudiced insight into the global mitomycin market and US, Japan and EU5 markets, in particular. It focuses on major market trends, key drivers and challenges. The clinical assessment of the drug and future outlook of the market through 2020 can also be found. Besides, the research offers the mitomycin therapy profile and a comprehensive guide to the gastric cancer disease market and TNM classification of the cancer.
Report Details:
Title: Mitomycin (Gastric Cancer) - Analysis and Forecasts to 2020
Date: Oct, 2011
Pages: 29
Price: US$ 2,000
Reports Contents:
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 INTRODUCTION
2.1 Gastric Cancer Market
2.2 Gastric Cancer Disease
2.3 GlobalData Pipeline Report Guidance
3 GASTRIC CANCER DISEASE: MARKET CHARACTERISTICS
3.1 Gastric Cancer Disease Market
3.2 Gastric Cancer Disease Market Forecasts
3.3 Drivers for the Gastric Cancer Disease Market
3.3.1 High Prevalence
3.3.2 High Incidence
3.3.3 High Survival Rate
3.3.4 High Mortality Rate
4 TUMOR NODE METASTASES (TNM) CLASSIFICATION OF GASTRIC CANCER
5 MITOMYCIN
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Approval History of Mitomycin
5.5 Factors Affecting Sales of Mitomycin
…
Market research reports on other markets for drugs used in diseases treatment are also available:
- Mitomycin (Bladder Cancer) - Analysis and Forecasts to 2020
- Methotrexate (Head and Neck Cancer) - Analysis and Forecasts to 2020
- Masitinib (Pancreatic Cancer) - Analysis and Forecasts to 2020
- Lyxumia (Type 2 Diabetes) – Analysis and Forecasts to 2020
- LY2189265 (Type 2 Diabetes) – Analysis and Forecasts to 2020
- Levemir (Type 2 Diabetes) – Analysis and Forecasts to 2020
- Lantus (Type 2 Diabetes) – Analysis and Forecasts to 2020
- Kombiglyze XR (Type 2 Diabetes) – Analysis and Forecasts to 2020
More new market research reports by the publisher can be found at GlobalData page.
CONTACTS
The Market Publishers, Ltd.
Mrs. Tanya Rezler
Tel: +44 208 123 2220
Fax: +44 207 900 3970
Analytics & News
